KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician

1Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2002; 2005: 74-108. doi: 10.3322/canjclin.55.2.74 Parkin DM Bray F Ferlay J Pisani P Global cancer statistics CA Cancer J Clin 2002 2005 74 108 10.3322/canjclin.55.2.7415761078Open DOISearch in Google Scholar

2Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol 2012; 4: 71-5. doi: 10.4251/wjgo.v4.i4.71 Moghimi-Dehkordi B Safaee A An overview of colorectal cancer survival rates and prognosis in Asia World J Gastrointest Oncol 2012 4 71 5 10.4251/wjgo.v4.i4.71333438222532879Open DOISearch in Google Scholar

3Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008; 134: 1296-310. doi: 10.1053/j.gastro.2008.02.098 Wolpin BM Mayer RJ Systemic treatment of colorectal cancer Gastroenterology 2008 134 1296 310 10.1053/j.gastro.2008.02.098252883218471507Open DOISearch in Google Scholar

4Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553-60. doi: 10.1200/JCO.2005.17.749 Kelly H Goldberg RM Systemic therapy for metastatic colorectal cancer: current options, current evidence J Clin Oncol 2005 23 4553 60 10.1200/JCO.2005.17.74916002847Open DOISearch in Google Scholar

5Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of RAS mutations in human colorectal cancers. Nature 1987; 327: 293-7. doi: 10.1038/327293a0 Bos JL Fearon ER Hamilton SR Verlaan-de Vries M van Boom JH van der Eb AJ et al Prevalence of RAS mutations in human colorectal cancers Nature 1987 327 293 7 10.1038/327293a03587348Open DOISearch in Google Scholar

6Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. Genotypic classification of colorectal adenocarcinoma. Cancer 1993; 71: 3827-38. 10.1002/1097-0142(19930615)71:12<3827::aid-cncr2820711207>3.0.co;2-n Finkelstein SD Sayegh R Christensen S Swalsky PA Genotypic classification of colorectal adenocarcinoma Cancer 1993 71 3827 38 10.1002/1097-0142(19930615)71:12<3827::aid-cncr2820711207>3.0.co;2-n10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-NSearch in Google Scholar

7Boughdady IS, Kinsella AR, Haboubi NY, Schofield PF. K-ras gene mutations in adenomas and carcinomas of the colon. Surg Oncol 1992; 1: 275-82. doi: 10.1016/0960-7404(92)90087-2 Boughdady IS Kinsella AR Haboubi NY Schofield PF K-ras gene mutations in adenomas and carcinomas of the colon Surg Oncol 1992 1 275 82 10.1016/0960-7404(92)90087-2Open DOISearch in Google Scholar

8Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009; 35: 262-71. doi: 10.1016/j.ctrv.2008.11.005 Heinemann V Stintzing S Kirchner T Boeck S Jung A Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR Cancer Treat Rev 2009 35 262 71 10.1016/j.ctrv.2008.11.005Open DOISearch in Google Scholar

9Gong J, Cho M, Sy M, Salgia R, Fakih M. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget 2017; 8: 42198-213. doi: 10.18632/oncotarget.15030 Gong J Cho M Sy M Salgia R Fakih M Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience Oncotarget 2017 8 42198 213 10.18632/oncotarget.15030Open DOISearch in Google Scholar

10Ibrahim T, Saer-Ghorra C, Trak-Smayra V, Nadiri S, Yazbeck C, Baz M, et al. Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution. Ann Saudi Med 2018; 38: 251-9. doi: 10.5144/0256-4947.2018.251 Ibrahim T Saer-Ghorra C Trak-Smayra V Nadiri S Yazbeck C Baz M et al Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution Ann Saudi Med 2018 38 251 9 10.5144/0256-4947.2018.251Open DOISearch in Google Scholar

11Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009; 219: 435-45. doi: 10.1002/path.2625 Abubaker J Bavi P Al-Haqawi W Sultana M Al-Harbi S Al-Sanea N et al Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma J Pathol 2009 219 435 45 10.1002/path.262519824059Open DOISearch in Google Scholar

12Zahrani A, Kandil M, Badar T, Abdelsalam M, Al-Faiar A, Ismail A. Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia. Tumori 2014; 100: 75-9. doi: 10.1700/1430.15819 Zahrani A Kandil M Badar T Abdelsalam M Al-Faiar A Ismail A Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia Tumori 2014 100 75 9 10.1700/1430.1581924675495Open DOISearch in Google Scholar

13Murtaza B, Bibi A, Rashid M, Khan Y, Chaudri M, Shakoori A. Spectrum of KRAS mutations in Pakistani colorectal cancer patients. Braz J Med Biol Res 2014; 47: 35-41. doi: 10.1590/1414-431X20133046 Murtaza B Bibi A Rashid M Khan Y Chaudri M Shakoori A Spectrum of KRAS mutations in Pakistani colorectal cancer patients Braz J Med Biol Res 2014 47 35 41 10.1590/1414-431X20133046393297124519090Open DOISearch in Google Scholar

14Segal G, Liebermann N, Klang S, Siegelmann-Daniel N, Beit-Or A, Klien B, et al. Identification of KRAS mutations in colorectal cancer patients in Israel. Harefuah 2011; 150: 447-50. Segal G Liebermann N Klang S Siegelmann-Daniel N Beit-Or A Klien B et al Identification of KRAS mutations in colorectal cancer patients in Israel Harefuah 2011 150 447 50Search in Google Scholar

15Marchoudi N, Joutei HAH, Jouali F, Fekkak J, Rhaissi H. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathol Biol 2013; 61: 273-6. doi: 10.1016/j.patbio.2013.05.004 Marchoudi N Joutei HAH Jouali F Fekkak J Rhaissi H Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer Pathol Biol 2013 61 273 6 10.1016/j.patbio.2013.05.00423849768Open DOISearch in Google Scholar

16Chaiyapan W, Duangpakdee P, Boonpipattanapong T, Kanngern S, Sangkhatthat S. Somatic mutations of K-RAS and BRAF in Thai colorectal cancer and their prognostic value. Asian Pac J Cancer Prev 2013; 14: 329-32. doi: 10.7314/apjcp.2013.14.1.329 Chaiyapan W Duangpakdee P Boonpipattanapong T Kanngern S Sangkhatthat S Somatic mutations of K-RAS and BRAF in Thai colorectal cancer and their prognostic value Asian Pac J Cancer Prev 2013 14 329 32 10.7314/apjcp.2013.14.1.32923534748Open DOISearch in Google Scholar

17Kafatos G, Niepel D, Lowe K, Jenkins-Anderson S, Westhead H, Garawin T, et al. RAS mutation prevalence among patients with metastatic colorectal cancer : a meta-analysis of real-world data. Biomark Med 2017; 11: 751-60. doi: 10.2217/bmm-2016-0358 Kafatos G Niepel D Lowe K Jenkins-Anderson S Westhead H Garawin T et al RAS mutation prevalence among patients with metastatic colorectal cancer : a meta-analysis of real-world data Biomark Med 2017 11 751 60 10.2217/bmm-2016-0358636777828747067Open DOISearch in Google Scholar

18Kwak MS, Cha JM, Cho YH, Kim SH, Yoon JY, Jeon JW, et al. Clinical predictors for KRAS codon 13 mutations in patients with colorectal cancer. J Clin Gastroenterol 2018; 52: 431-6. doi: 10.1097/MCG.0000000000000809 Kwak MS Cha JM Cho YH Kim SH Yoon JY Jeon JW et al Clinical predictors for KRAS codon 13 mutations in patients with colorectal cancer J Clin Gastroenterol 2018 52 431 6 10.1097/MCG.000000000000080928277374Open DOISearch in Google Scholar

19Dobre M, Dinu DE, Panaitescu E, Birla RE, Iosif CI, Boeriu M, et al. KRAS gene mutations – prognostic factor in colorectal cancer? Rom J Morphol Embryol 2015; 56(2 Suppl): 671-8. PMID: 26429158 Dobre M Dinu DE Panaitescu E Birla RE Iosif CI Boeriu M et al KRAS gene mutations – prognostic factor in colorectal cancer? Rom J Morphol Embryol 2015 562 Suppl 671 8 PMID: 2642915810.26226/morressier.57a2f938d462b8028d88feffSearch in Google Scholar

20Van Cutsem, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17. doi: 10.1056/NEJMoa0805019 Van Cutsem Köhne CH Hitre E Zaluski J Chang Chien CR Makhson A et al Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 2009 360 1408 17 10.1056/NEJMoa080501919339720Open DOISearch in Google Scholar

21Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-46. doi: 10.1093/annonc/mdq632 Bokemeyer C Bondarenko I Hartmann JT de Braud F Schuch G Zubel A et al Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 2011 22 1535 46 10.1093/annonc/mdq63221228335Open DOISearch in Google Scholar

22Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/ RAF, PIK3CA genotypes. BMC Cancer 2013; 13: 49. doi: 10.1186/1471-2407-13-49 Pentheroudakis G Kotoula V De Roock W Kouvatseas G Papakostas P Makatsoris T et al Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/ RAF, PIK3CA genotypes BMC Cancer 2013 13 49 10.1186/1471-2407-13-49359969723374602Open DOISearch in Google Scholar

23Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti- EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012; 23: 1518-25. doi: 10.1093/annonc/mdr464 Mao C Yang ZY Hu XF Chen Q Tang JL PIK3CA exon 20 mutations as a potential biomarker for resistance to anti- EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis Ann Oncol 2012 23 1518 25 10.1093/annonc/mdr46422039088Open DOISearch in Google Scholar

24Brulé SY, Jonker DJ, Karapetis CS, O’Callaghan CJ, Moore MJ, Wong R, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015; 51: 1405-14. doi: 10.1016/j.ejca.2015.03.015 Brulé SY Jonker DJ Karapetis CS O’Callaghan CJ Moore MJ Wong R et al Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17 Eur J Cancer 2015 51 1405 14 10.1016/j.ejca.2015.03.01525979833Open DOISearch in Google Scholar

25Petrelli F, Tomasello G, Borgonov K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer. A systematic review and meta-analysis. JAMA Oncol 2016; 3: 211-19. doi: 10.1001/jamaoncol.2016.4227 Petrelli F Tomasello G Borgonov K Ghidini M Turati L Dallera P et al Prognostic survival associated with left-sided vs right-sided colon cancer A systematic review and meta-analysis JAMA Oncol 2016 3 211 19 10.1001/jamaoncol.2016.422727787550Open DOISearch in Google Scholar

26Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-7. doi: 10.1200/ JCO.2012.42.2592 Tejpar S Celik I Schlichting M Sartorius U Bokemeyer C Van Cutsem E Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 2012 30 3570 7 10.1200/ JCO.2012.42.2592Open DOISearch in Google Scholar

27Chen J, Ye Y, Sun H, Shi G. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol 2013; 71: 265-72. doi: 10.1007/s00280-012-2005-9 Chen J Ye Y Sun H Shi G Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis Cancer Chemother Pharmacol 2013 71 265 72 10.1007/s00280-012-2005-923090619Open DOISearch in Google Scholar

28Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-65. doi: 10.1200/ JCO.2012.45.1492 Peeters M Douillard JY Van Cutsem E Siena S Zhang K Williams R et al Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab J Clin Oncol 2013 31 759 65 10.1200/ JCO.2012.45.1492Open DOISearch in Google Scholar

29Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten Ras mutations in patients with colorectal cancer: the multicenter ‘‘RASCAL” study. J Natl Cancer Inst 1998; 90: 675-84. doi: 10.1093/jnci/90.9.675 Andreyev HJ Norman AR Cunningham D Oates JR Clarke PA Kirsten Ras mutations in patients with colorectal cancer: the multicenter ‘‘RASCAL” study J Natl Cancer Inst 1998 90 675 84 10.1093/jnci/90.9.6759586664Open DOISearch in Google Scholar

30Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study onthe PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74. doi: 10.1200/JCO.2009.23.3452 Roth AD Tejpar S Delorenzi M Yan P Fiocca R Klingbiel D et al Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study onthe PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 2010 28 466 74 10.1200/JCO.2009.23.345220008640Open DOISearch in Google Scholar

31Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009; 15: 7322-9. doi: 10.1158/1078-0432.CCR-09-1570 Ogino S Meyerhardt JA Irahara N Niedzwiecki D Hollis D Saltz LB et al KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 Clin Cancer Res 2009 15 7322 9 10.1158/1078-0432.CCR-09-1570278768919934290Open DOISearch in Google Scholar

32Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65. doi: 10.1056/NEJMoa0804385 Karapetis CS Khambata-Ford S Jonker DJ O’Callaghan CJ Tu D Tebbutt NC et al K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 2008 359 1757 65 10.1056/NEJMoa080438518946061Open DOISearch in Google Scholar

33De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62. doi: 10.1016/S1470-2045(10)70130-3 De Roock W Claes B Bernasconi D De Schutter J Biesmans B Fountzilas G et al Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 2010 11 753 62 10.1016/S1470-2045(10)70130-320619739Open DOISearch in Google Scholar

34Schiripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer 2015; 136: 83-90. doi: 10.1002/ijc.28955 Schiripa M Cremolini C Loupakis F Morvillo M Bergamo F Zoratto F et al Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer Int J Cancer 2015 136 83 90 10.1002/ijc.2895524806288Open DOISearch in Google Scholar

35Au HJ, Karapetis CS, O’Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol 2009; 27: 1822-8. doi: 10.1200/ JCO.2008.19.6048 Au HJ Karapetis CS O’Callaghan CJ Tu D Moore MJ Zalcberg JR et al Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial J Clin Oncol 2009 27 1822 8 10.1200/ JCO.2008.19.6048Open DOISearch in Google Scholar

36Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2011; 2: 232-60. doi: 10.1177/1947601911407323 Matallanas D Birtwistle M Romano D Zebisch A Rauch J von Kriegsheim A et al Raf family kinases: old dogs have learned new tricks Genes Cancer 2011 2 232 60 10.1177/1947601911407323312862921779496Open DOISearch in Google Scholar

37Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF- ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-67. doi: 10.1016/s0092-8674(04)00215-6 Wan PT Garnett MJ Roe SM Lee S Niculescu-Duvaz D Good VM et al Mechanism of activation of the RAF- ERK signaling pathway by oncogenic mutations of B-RAF Cell 2004 116 855 67 10.1016/s0092-8674(04)00215-615035987Open DOISearch in Google Scholar

38Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54. doi: 10.1038/ nature00766 Davies H Bignell GR Cox C Stephens P Edkins S Clegg S et al Mutations of the BRAF gene in human cancer Nature 2002 417 949 54 10.1038/ nature00766Open DOISearch in Google Scholar

39Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-14. doi: 10.1016/S0140-6736(11)60613-2 Maughan TS Adams RA Smith CG Meade AM Seymour MT Wilson RH et al Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 2011 377 2103 14 10.1016/S0140-6736(11)60613-2315941521641636Open DOISearch in Google Scholar

40Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009; 101: 465-72. doi: 10.1038/sj.bjc.6605164 Souglakos J Philips J Wang R Marwah S Silver M Tzardi M et al Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer Br J Cancer 2009 101 465 72 10.1038/sj.bjc.6605164272023219603024Open DOISearch in Google Scholar

41Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from theMRC FOCUS trial. J Clin Oncol 2009; 27: 5931-7. doi: 10.1200/JCO.2009.22.4295 Richman SD Seymour MT Chambers P Elliott F Daly CL Meade AM et al KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from theMRC FOCUS trial J Clin Oncol 2009 27 5931 7 10.1200/JCO.2009.22.429519884549Open DOISearch in Google Scholar

42Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-32. doi: 10.1002/cncr.26086 Tran B Kopetz S Tie J Gibbs P Jiang ZQ Lieu CH et al Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer Cancer 2011 117 4623 32 10.1002/cncr.26086425747121456008Open DOISearch in Google Scholar

43Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104: 856-62. doi: 10.1038/bjc.2011.19 Yokota T Ura T Shibata N Takahari D Shitara K Nomura M et al BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer Br J Cancer 2011 104 856 62 10.1038/bjc.2011.19304821021285991Open DOISearch in Google Scholar

44Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, et al. Optimizing targeted therapeutic develop- ment: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011; 128: 207584. doi: 10.1002/ijc.25555 Tie J Gibbs P Lipton L Christie M Jorissen RN Burgess AW et al Optimizing targeted therapeutic develop- ment: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation Int J Cancer 2011 128 207584 10.1002/ijc.2555520635392Open DOISearch in Google Scholar

45Li HT, Lu YY, An YX, Wang X, Zhao QC. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep 2011; 25: 1691-97. doi: 10.3892/or.2011.1217 Li HT Lu YY An YX Wang X Zhao QC KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer Oncol Rep 2011 25 1691 97 10.3892/or.2011.121721424126Open DOISearch in Google Scholar

46Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clin Chim Acta 2012; 413: 1605-11. doi: 10.1016/j.cca.2012.04.029 Hsieh LL Er TK Chen CC Hsieh JS Chang JG Liu TC Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population Clin Chim Acta 2012 413 1605 11 10.1016/j.cca.2012.04.02922579930Open DOISearch in Google Scholar

47Shen Y, Wang J, Han X, Yang H, Wang S, Lin D et al. Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One 2013; 8: e81628. doi: 10.1371/journal.pone.0081628 Shen Y Wang J Han X Yang H Wang S Lin D et al Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine PLoS One 2013 8 e81628 10.1371/journal.pone.0081628385824224339949Open DOISearch in Google Scholar

48Lo L, Price T, Young J, Townsend A. BRAF mutation in colorectal cancer. [cited 10 Feb 2019]. Available at: https://www.intechopen.com/books/colorectal-cancer-from-pathogenesis-to-treatment/braf-mutation-in-colorectal-cancer doi: 10.5772/62226 Lo L Price T Young J Townsend A BRAF mutation in colorectal cancer [cited 10 Feb 2019]. Available at https://www.intechopen.com/books/colorectal-cancer-from-pathogenesis-to-treatment/braf-mutation-in-colorectal-cancer 10.5772/62226Open DOISearch in Google Scholar

49Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53: 1137-44. doi: 10.1136/gut.2003.037671 Kambara T Simms LA Whitehall VL Spring KJ Wynter CV Walsh MD et al BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum Gut 2004 53 1137 44 10.1136/gut.2003.037671177413015247181Open DOISearch in Google Scholar

50Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-32. doi: 10.1002/cncr.26086 Tran B Kopetz S Tie J Gibbs P Jiang ZQ Lieu CH et al Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer Cancer 2011 117 4623 32 10.1002/cncr.26086425747121456008Open DOISearch in Google Scholar

51Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, et al. BRAF V600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One 2014; 2014; 9: e90607. doi: 10.1371/journal.pone.0090607 Chen D Huang JF Liu K Zhang LQ Yang Z Chuai ZR et al BRAF V600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis PLoS One 2014 2014 9 e90607 10.1371/journal.pone.0090607394092424594804Open DOISearch in Google Scholar

52Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009; 27: 1477-84. doi: 10.1200/ JCO.2008.18.654 Ogino S Nosho K Kirkner GJ Shima K Irahara N Kure S et al PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer J Clin Oncol 2009 27 1477 84 10.1200/ JCO.2008.18.654Open DOISearch in Google Scholar

53Zarkavelis G, Boussiosa S, Papadakia A, Katsanos KH, Christodoulou DK, Pentheroudakis G. Current and future biomarkers in colorectal cancer. Ann Gastroenterol 2017; 30: 613-21. doi: 10.20524/aog.2017.0191 Zarkavelis G Boussiosa S Papadakia A Katsanos KH Christodoulou DK Pentheroudakis G Current and future biomarkers in colorectal cancer Ann Gastroenterol 2017 30 613 21 10.20524/aog.2017.0191567028029118555Open DOISearch in Google Scholar

54Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelation- ship between genetics and epigenetics. Carcinogenesis 2008; 29: 673-80. doi: 10.1093/carcin/bgm228 Imai K Yamamoto H Carcinogenesis and microsatellite instability: the interrelation- ship between genetics and epigenetics Carcinogenesis 2008 29 673 80 10.1093/carcin/bgm22817942460Open DOISearch in Google Scholar

55Jensen LH, Lindebjerg J, Byriel L, Kolvraa S, Crüger DG. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. Colorectal Dis 2008; 10: 490-7. doi: 10.1111/j.1463-1318.2007.01378.x Jensen LH Lindebjerg J Byriel L Kolvraa S Crüger DG Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency Colorectal Dis 2008 10 490 7 10.1111/j.1463-1318.2007.01378.x17868408Open DOISearch in Google Scholar

56Rahner N, Friedrichs N, Steinke V, Aretz S, Friedl W, Buettner R, et al. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol 2008; 214: 10-16. doi: 10.1002/path.2263 Rahner N Friedrichs N Steinke V Aretz S Friedl W Buettner R et al Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome J Pathol 2008 214 10 16 10.1002/path.226317973250Open DOISearch in Google Scholar

57Domingo E, Laiho P, Ollikainen M, Pinto L, Wang A, French J, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41: 664-8. doi: 10.1136/jmg.2004.020651 Domingo E Laiho P Ollikainen M Pinto L Wang A French J et al BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing J Med Genet 2004 41 664 8 10.1136/jmg.2004.020651173588515342696Open DOISearch in Google Scholar

58Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-15. doi: 10.1016/S1470-2045(15)00122-9 Cremolini C Loupakis F Antoniotti C Lupi C Sensi E Lonardi S et al FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study Lancet Oncol 2015 16 1306 15 10.1016/S1470-2045(15)00122-926338525Open DOISearch in Google Scholar

59Sanz- Garcia E, Argiles G, Elez E, Tabernero J. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Ann Oncol 2017; 28: 2648-57. doi: 10.1093/annonc/mdx401 Sanz- Garcia E Argiles G Elez E Tabernero J BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives Ann Oncol 2017 28 2648 57 10.1093/annonc/mdx40129045527Open DOISearch in Google Scholar

60Renaud S, Romain B, Falcoz PE, Olland A, Santelmo N, Brigand C, et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer 2015; 112: 720-8. doi: 10.1038/bjc.2014.499 Renaud S Romain B Falcoz PE Olland A Santelmo N Brigand C et al KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer Br J Cancer 2015 112 720 8 10.1038/bjc.2014.499433348725688918Open DOISearch in Google Scholar

61Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-75. doi: 10.1016/j.ejca.2012.02.057 Bokemeyer C Van Cutsem E Rougier P Ciardiello F Heeger S Schlichting, et al Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 2012 48 1466 75 10.1016/j.ejca.2012.02.05722446022Open DOISearch in Google Scholar

62Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34. doi: 10.1056/NEJMoa1305275 Douillard JY Oliner KS Siena S Tabernero J Burkes R Barugel M et al Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 2013 369 1023 34 10.1056/NEJMoa130527524024839Open DOISearch in Google Scholar

63Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013; 14: 749-59. doi: 10.1016/S1470-2045(13)70163-3 Seymour MT Brown SR Middleton G Maughan T Richman S Gwyther S et al Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial Lancet Oncol 2013 14 749 59 10.1016/S1470-2045(13)70163-3369971323725851Open DOISearch in Google Scholar

64Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O’Callaghan CJ, Marginean C, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17. Clin Cancer Res 2014; 20: 744-53. doi: 10.1158/1078-0432.CCR-13-0606 Karapetis CS Jonker D Daneshmand M Hanson JE O’Callaghan CJ Marginean C et al PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17 Clin Cancer Res 2014 20 744 53 10.1158/1078-0432.CCR-13-060624218517Open DOISearch in Google Scholar

65Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 107-16. doi: 10.1093/annonc/mdt523 Peeters M Price TJ Cervantes A Sobrero AF Ducreux M Hotko Y et al Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer Ann Oncol 2014 25 107 16 10.1093/annonc/mdt52324356622Open DOISearch in Google Scholar

66Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587-94. doi: 10.1016/j.ejca.2015.01.054 Pietrantonio F Petrelli F Coinu A Di Bartolomeo M Borgonovo K Maggi C et al Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis Eur J Cancer 2015 51 587 94 10.1016/j.ejca.2015.01.05425673558Open DOISearch in Google Scholar

67Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888-94. doi: 10.1038/ bjc.2015.173 Rowland A Dias MM Wiese MD Kichenadasse G McKinnon RA Karapetis CS et al Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer Br J Cancer 2015 112 1888 94 10.1038/ bjc.2015.173Open DOISearch in Google Scholar

68Yuan ZX, Wang XY, Qin QY, Chen DF, Zhong QH, Wang L, et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One 2013; 8: e65995. doi: 10.1371/journal.pone Yuan ZX Wang XY Qin QY Chen DF Zhong QH Wang L et al The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis PLoS One 2013 8 e65995 10.1371/journal.poneOpen DOISearch in Google Scholar

69Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014; 50: 57-63. doi: 10.1016/j.ejca Loupakis F Cremolini C Salvatore L Masi G Sensi E Schirripa M et al FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer Eur J Cancer 2014 50 57 63 10.1016/j.ejcaOpen DOISearch in Google Scholar

70Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, et al. BEACON CRC study safety lead-in (SLI) in patients with BRAF ^V600E metastatic colorectal cancer: Binimetinib, Encorafenib and Cetuximab Triplet Therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol 2019: 37: 1460-9. doi: 10.1200/JCO.18.02459 Van Cutsem E Huijberts S Grothey A Yaeger R Cuyle PJ Elez E et al BEACON CRC study safety lead-in (SLI) in patients with BRAF ^V600E metastatic colorectal cancer: Binimetinib, Encorafenib and Cetuximab Triplet Therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study J Clin Oncol 2019 37 1460 9 10.1200/JCO.18.02459737069930892987Open DOISearch in Google Scholar

71Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F. HER 2/neu protein expression in colorectal cancer. BMC Cancer 2006; 6: 123. doi: 10.1186/1471-2407-6-123 Schuell B Gruenberger T Scheithauer W Zielinski Ch Wrba F HER 2/neu protein expression in colorectal cancer BMC Cancer 2006 6 123 10.1186/1471-2407-6-123147587616681853Open DOISearch in Google Scholar

72Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 ( HER2) oncogene in colorectal cancer. Ann Oncol 2018; 29: 1108-19. doi: 10.1093/ annonc/mdy100 Siena S Sartore-Bianchi A Marsoni S Hurwitz HI McCall SJ Penault-Llorca F et al Targeting the human epidermal growth factor receptor 2 ( HER2) oncogene in colorectal cancer Ann Oncol 2018 29 1108 19 10.1093/ annonc/mdy100Open DOISearch in Google Scholar

73Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, et al. Her2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One 2014; 9: e98528. doi: 10.1371/journal.pone Seo AN Kwak Y Kim DW Kang SB Choe G Kim WH et al Her2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression PLoS One 2014 9 e98528 10.1371/journal.poneOpen DOISearch in Google Scholar

74Ingold Heppner B, Behrens HM, Balschun K, Haag J, Krüger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer 2014; 111: 1977-84. doi: 10.1038/bjc.2014.483 Ingold Heppner B Behrens HM Balschun K Haag J Krüger S Becker T et al HER2/neu testing in primary colorectal carcinoma Br J Cancer 2014 111 1977 84 10.1038/bjc.2014.483422962925211663Open DOISearch in Google Scholar

75Missiaglia E, Jacobs B, D’Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014; 25: 1995-2001. doi: 10.1093/annonc/ mdu275 Missiaglia E Jacobs B D’Ario G Di Narzo AF Soneson C Budinska E et al Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features Ann Oncol 2014 25 1995 2001 10.1093/annonc/ mdu275Open DOISearch in Google Scholar

76Nam SK, Yun S, Koh J, Kwak Y, Seo AN, Park KU, et al. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. PLoS One 2016; 11: e0151865. doi: 10.1371/journal.pone Nam SK Yun S Koh J Kwak Y Seo AN Park KU et al BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis PLoS One 2016 11 e0151865 10.1371/journal.poneOpen DOISearch in Google Scholar

77Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (“Xenopatient”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery 2011; 1: 508-23. doi: 10.1158/2159-8290 Bertotti A Migliardi G Galimi F Sassi F Torti D Isella C et al A molecularly annotated platform of patient-derived xenografts (“Xenopatient”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer Cancer Discovery 2011 1 508 23 10.1158/2159-8290Open DOISearch in Google Scholar

78Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3: 99ra86. doi: 10.1126/ scitranslmed.3002442 Yonesaka K Zejnullahu K Okamoto I Satoh T Cappuzzo F Souglakos J et al Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Sci Transl Med 2011 3 99ra86 10.1126/ scitranslmed.3002442Open DOISearch in Google Scholar

79Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 2013; 108: 668-75. doi: 10.1038/bjc.2013 Martin V Landi L Molinari F Fountzilas G Geva R Riva A et al HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients Br J Cancer 2013 108 668 75 10.1038/bjc.2013Open DOISearch in Google Scholar

80Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998; 55: 548-55. doi: 10.1159/000011911 Osako T Miyahara M Uchino S Inomata M Kitano S Kobayashi M Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival Oncology 1998 55 548 55 10.1159/0000119119778622Open DOISearch in Google Scholar

81Kapitanovic S, Radosevic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112: 1103-13. doi: 10.1016/S0016-5085(97)70120-3 Kapitanovic S Radosevic S Kapitanovic M Andelinovic S Ferencic Z Tavassoli M et al The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer Gastroenterology 1997 112 1103 13 10.1016/S0016-5085(97)70120-3Open DOISearch in Google Scholar

82Li C, Liu DR, Ye LY, Huang LN, Jaiswai S, Li XW, et al. HER-2 overexpression and survival in colorectal cancer: a meta-analysis. J Zhejiang Univ Sci B 2014; 15: 582-9. doi: 10.1631/jzus.B1300258 Li C Liu DR Ye LY Huang LN Jaiswai S Li XW et al HER-2 overexpression and survival in colorectal cancer: a meta-analysis J Zhejiang Univ Sci B 2014 15 582 9 10.1631/jzus.B1300258411685524903996Open DOISearch in Google Scholar

83Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn 2008; 10: 301-7. doi: 10.2353/jmoldx.2008.080062 Zhang L Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome Part II. The utility of microsatellite instability testing. J Mol Diagn 2008 10 301 7 10.2353/jmoldx.2008.080062243819718556776Open DOISearch in Google Scholar

84Ward R, Meagher A, Tomlinson I, O’Connor T, Norrie M, Wu R, et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 2001; 48: 821-9. doi: 10.1136/gut.48.6.821 Ward R Meagher A Tomlinson I O’Connor T Norrie M Wu R et al Microsatellite instability and the clinicopathological features of sporadic colorectal cancer Gut 2001 48 821 9 10.1136/gut.48.6.821172832411358903Open DOISearch in Google Scholar

85Tiwari AK, Roy HK, Lynch HT. Lynch syndrome in the 21^st century: clinical perspectives. QJM 2016; 109: 151-8. doi: 10.1093/qjmed/hcv137 Tiwari AK Roy HK Lynch HT Lynch syndrome in the 21^st century: clinical perspectives QJM 2016 109 151 8 10.1093/qjmed/hcv13726224055Open DOISearch in Google Scholar

86Ashktorab H, Ahuja S, Kannan L, Lior X, Ellis NA, Xicola RM, et al. A meta-analysis of MSI frequency and race in colorectal cancer. Oncotarget 2016; 7: 34546-57. doi: 10.18632/oncotarget.8945 Ashktorab H Ahuja S Kannan L Lior X Ellis NA Xicola RM et al A meta-analysis of MSI frequency and race in colorectal cancer Oncotarget 2016 7 34546 57 10.18632/oncotarget.8945508517527120810Open DOISearch in Google Scholar

87Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018; 36: 773-9. doi: 10.1200/JCO.2017.76.9901 Overman MJ Lonardi S Wong KYM Lenz HJ Gelsomino F Aglietta M et al Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer J Clin Oncol 2018 36 773 9 10.1200/JCO.2017.76.990129355075Open DOISearch in Google Scholar

88Fujiyoshi K, Yamamoto G, Takenoya T, Takahashi A, Arai Y, Yamada M, et al. Metastatic pattern of stage IV colorectal cancer with high-frequency micro-satellite instability as a prognostic factor. Anticancer Res 2017; 37: 239-47. doi: 10.21873/anticanres.11313 Fujiyoshi K Yamamoto G Takenoya T Takahashi A Arai Y Yamada M et al Metastatic pattern of stage IV colorectal cancer with high-frequency micro-satellite instability as a prognostic factor Anticancer Res 2017 37 239 47 10.21873/anticanres.1131328011498Open DOISearch in Google Scholar

89Kawakami H, Zaanan A, Sinicrope FA. MSI testing and its role in management of colorectal cancer. Curr Treat Options Oncol 2015; 16: 30. doi: 10.1007/s11864-015-0348-2 Kawakami H Zaanan A Sinicrope FA MSI testing and its role in management of colorectal cancer Curr Treat Options Oncol 2015 16 30 10.1007/s11864-015-0348-2459419026031544Open DOISearch in Google Scholar